Monod Bio Receives Award to Develop a New Diagnostic Test for Preeclampsia using AI-designed Proteins - Monod Bio

▤ Summary

Monod Bio secured a $750,000 grant from Grand Challenges, an initiative of the Gates Foundation, to develop a new point-of-care diagnostic for preeclampsia. The company will use its AI-powered de novo protein design platform to measure key biomarkers and deliver results in under 15 minutes. The diagnostic targets low-resource settings where current biomarker-based tests are too costly or too complex to deploy widely. Monod Bio says the project advances its broader goal of bringing accessible protein-based diagnostics to global health markets.

$ Funding

▦ Linked Companies